A bidding war over U.S. biotech Metsera was coming to a head on Thursday, with Danish drugmaker Novo Nordisk locked in a $10 ...

Pfizer and Novo Nordisk's fight for obesity drug developer Metsera ratcheted up on Tuesday, as both companies submitted ...

Pfizer and Novo Nordisk are in a takeover clash over the obesity biotech Metsera, while some House Republicans warm to ...

Novo Nordisk is raising the stakes in its push to outbid rival Pfizer for the development-stage drugmaker Metsera.

The Danish company’s latest offer is more than 30% about what Pfizer initially agreed to pay, not counting potential ...

The lawsuit says the merger would solidify Novo Nordisk’s market position as a leader in the field of obesity drugs by ...

The new offer from Novo Nordisk constitutes a superior company proposal, Metsera says.

Another quarterly earnings announcement from Novo Nordisk and another downgrade to earnings guidance from the Danish ...

Pressure from the FTC and Pfizer is building around Novo Nordisk’s bid to snatch obesity biotech Metsera: The antitrust ...

The court’s decision allows Metsera to walk away from its previous acquisition agreement with Pfizer in favor of Novo Nordisk ...

A judge denied Pfizer's ( PFE) request to temporarily block Novo Nordisk's ( NVO) $10 billion bid for Metsera. Metsera rose 2 ...

Novo Nordisk made a much higher offer to acquire a biotech Pfizer was already set to buy out. Losing this battle would be more damaging to Pfizer than to Novo Nordisk. Even so, both companies look ...